Interview: AstraZeneca sees Japan as a land of opportunity
This article was originally published in Scrip
Compared with the doom and gloom pervading the industry in some other major markets, the generally brighter outlook in Japan and the rest of Asia is providing a welcome contrast for Mark Mallon.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.